Shrinking revenues and increasing costs, YOY: seekingalpha.com/symbol/ADVM/income-statement
Better products from much larger competitors: seekingalpha.com/news/3505590-adverum-regenxbio-go-opposite-ways-wet-amd-data
EV/EBITDA: -5
EPS: -1
Up 176% for the year
Might be worth targeting a 30% decline in the mid term? Thoughts?
Better products from much larger competitors: seekingalpha.com/news/3505590-adverum-regenxbio-go-opposite-ways-wet-amd-data
EV/EBITDA: -5
EPS: -1
Up 176% for the year
Might be worth targeting a 30% decline in the mid term? Thoughts?
Penafian
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Penafian
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.